<DOC>
	<DOCNO>NCT01417169</DOCNO>
	<brief_summary>This study evaluate safety prophylaxis effect micafungin hematopoietic stem cell transplantation . Micafungin administer confirmation neutrophil engraftment treatment failure .</brief_summary>
	<brief_title>Micafungin Prevention Study Invasive Fungal Disease Pediatric &amp; Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>The purpose study evaluate absence proven , probable , possible , suspected invasive fungal disease ( IFDs ) end prophylaxis therapy 4 week stop micafungin prophylaxis Autologous hematopoietic stem cell transplantation pediatric adolescent neutropenia patient . Patients receive micafungin early follow : 1 ) neutrophil engraftment ; 2 ) development proven , provable , possible suspect invasive fungal disease ; 3 ) development unacceptable drug toxicity ; 4 ) withdrawal study participation discontinuation study treatment . Safety profile micafungin also evaluate .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>1 . Patients receive autologous hematopoietic stem cell transplantation include 2nd autologous transplantation 2 . Under 21 year old , pediatric , adolescent patient . 1 . Aspartate transaminase alanine transaminase level &gt; 5 time UNL 2 . Bilirubin &gt; 2.5 time UNL 3 . History allergy , sensitivity , serious reaction echinocandin 4 . Invasive fungal disease time enrolment 5 . Systemic antifungal therapy within 72 hrs administration first dose study drug 6 . Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>